<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169791</url>
  </required_header>
  <id_info>
    <org_study_id>NSH 1074</org_study_id>
    <secondary_id>X16035</secondary_id>
    <nct_id>NCT02169791</nct_id>
  </id_info>
  <brief_title>Nonmyeloablative Haploidentical Transplant Followed by MLN9708</brief_title>
  <official_title>A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In an attempt to reduce relapse risk and improve outcomes following haploidentical
      transplantation for patients with high risk hematologic malignancies, the investigators will
      implement several strategies to augment the well documented effect of NK cell alloreactivity
      seen in HLA-mismatched transplantation. These strategies include (1) choosing potential
      haploidentical donors for optimal NK-alloreactivity, (2) utilizing proteasome inhibition
      post-transplant with MLN9708 to both sensitize tumor cells to NK cytotoxicity and protect
      against graft-versus-host disease (GVHD), and (3) eliminating mycophenolate mofetil from the
      post-transplant immunosuppression regimen to improve NK cell reconstitution following
      haploidentical peripheral blood stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview of Study Design:

      In an attempt to reduce relapse risk and improve outcomes following haploidentical
      transplantation for patients with high risk hematologic malignancies, the investigators will
      implement several strategies to augment the well documented effect of NK cell alloreactivity
      seen in HLA-mismatched transplantation. These strategies include (1) choosing potential
      haploidentical donors for optimal NK-alloreactivity, (2) utilizing proteasome inhibition
      post-transplant with MLN9708 to both sensitize tumor cells to NK cytotoxicity and protect
      against graft-versus-host disease (GVHD), and (3) eliminating mycophenolate mofetil from the
      post-transplant immunosuppression regimen to improve NK cell reconstitution following
      haploidentical peripheral blood stem cell transplantation.

      Patients will receive a nonmyeloablative haploidentical transplant using a T-cell replete
      allograft and post-transplant cyclophosphamide as previously described at our center (Bashey
      et al. J Clin Oncol. 2013; 31(10):1310-6). MLN9708 will be administered once weekly for 3
      weeks on a 28 day cycle for one-year post-transplant. Post-transplant immunosuppression will
      consist of tacrolimus only (MLN9708 will substitute for mycophenolate mofetil as the second
      GVHD prophylactic medication).

      The primary endpoint of this trial will be the risk of relapse and/or progression at one-year
      post-transplant. Experience from the literature suggests that following a nonmyeloablative
      haploidentical transplant using post-transplant cyclophosphamide (haplo-pCy), the risk of
      relapse is approximately 50% at one year post-transplant. It is hoped that under this
      protocol, this rate will be at most 25%. Thus the investigators statistically formalize this
      study by testing the null hypothesis that p, the PFS rate is 0.25 or less versus the
      alternative hypothesis that p is greater than 0.5. A sample size of 25 patients gives 90%
      power with an alpha=0.05, using the formula for a one sample binomial (two-sided) test of a
      proportion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Relapse and progression</measure>
    <time_frame>1 year</time_frame>
    <description>To estimate the incidence of relapse/progression at one-year post-transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>To obtain estimates of overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free</measure>
    <time_frame>3 years</time_frame>
    <description>To obtain estimates of event-free survival (EFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapsed mortality</measure>
    <time_frame>3 years</time_frame>
    <description>To obtain estimate of non-relapse mortality (NRM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>3 years</time_frame>
    <description>To obtain estimates of acute and chronic graft-versus-host disease (GVHD).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Lymphomas</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Haploidentical Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <description>MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.</description>
    <arm_group_label>Haploidentical Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability of a 3/6 - 5/6 matched (HLA-A, B, DR) related donor

          -  Donor must have negative HLA cross-match in the host vs. graft direction.

          -  Donor must be willing to donate mobilized peripheral blood stem cells

          -  Age ≥ 18 years

          -  Karnofsky status ≥ 70%

          -  One of the following high-risk malignancies:

          -  Chronic Myelogenous Leukemia (chronic phase, resistant and/or intolerant to tyrosine
             kinase inhibitors (OR) accelerated phase (OR) blast crisis in 2nd chronic phase
             following induction chemotherapy)

          -  Acute Myelogenous Leukemia (2nd or subsequent complete remission [CR] (OR) Primary
             induction chemotherapy failure, but subsequently entered into a CR(OR) 1st CR with
             poor risk cytogenetics or molecular markers; or arising from preceding hematological
             disease)

          -  Myelodysplastic Syndrome (treatment-related, monosomy 7 or complex cytogenetics, IPSS
             score of 1.5 or greater, Chronic myelomonocytic leukemia [CMML])

          -  Acute lymphocytic leukemia/lymphoblastic lymphoma (2nd or subsequent CR (OR) Primary
             induction chemotherapy failure, but subsequently entered into a CR (OR) 1st CR with
             poor risk cytogenetics)

          -  Chronic Lymphocytic Leukemia / Prolymphocytic Leukemia (Duration of remission &lt;12
             months after receiving chemotherapy with a nucleoside analog (OR) High risk features
             (i.e. 17p deletion), (OR) Second or subsequent relapse)

          -  Hodgkin's or Non-Hodgkin's Lymphoma (including low-grade, mantle cell, and
             intermediate-grade/diffuse) (Previously treated disease that has either relapsed or
             failed to respond adequately to conventional-dose therapy or autologous
             transplantation (AND) Chemoresponsive to most recent salvage therapy

          -  Multiple Myeloma (Presence of a poor risk cytogenetic abnormality [i.e. 17p, t(4;14)],
             Relapse post autologous transplant)

        Exclusion Criteria:

          -  Poor cardiac function: left ventricular ejection fraction &lt;40%

          -  Poor pulmonary function: FEV1, FVC, or DLCO &lt;50% predicted

          -  Poor liver function: bilirubin &gt;2.5 mg/dl (not due to hemolysis, Gilbert's or primary
             malignancy), AST/ALT &gt; 3X ULN

          -  Poor renal function: Creatinine &gt;2.0 mg/dl or creatinine clearance (calculated
             creatinine clearance is permitted) &lt; 40 mL/min

          -  Ongoing or active systemic infection, active hepatitis B or C virus infection, or
             known human immunodeficiency virus (HIV) positive.

          -  Women of childbearing potential who currently are pregnant or who are not practicing
             adequate contraception

          -  Patients who have any debilitating medical or psychiatric illness which would preclude
             their giving informed consent or their receiving optimal treatment and follow-up.

          -  Systemic treatment, within 14 days before the first dose of MLN9708, with strong
             strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole,
             ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin,
             rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo
             biloba or St. John's wort.

          -  Patient has &gt;/= Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical
             examination during the screening period.

          -  Participation in other clinical trials, including those with other investigational
             agents not included in this trial, within 21days of the start of this trial and
             throughout the duration of this trial.

          -  Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before study enrollment.

          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,
             unstable angina, or myocardial infarction within the past 6 months.

          -  Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

          -  Known GI disease or GI procedure that could interfere with the oral absorption or
             tolerance of MLN9708 including difficulty swallowing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Scott Solomon, MD</last_name>
    <phone>404-255-1930</phone>
    <email>ssolomon@bmtga.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacey Brown, BA</last_name>
    <phone>404-851-8238</phone>
    <email>stacey.brown@northside.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Solomon, MD</last_name>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Brown, BA</last_name>
      <phone>404-851-8238</phone>
      <email>stacey.brown@northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>H. Kent Holland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asad Bashey, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence E Morris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997 May;15(5):1767-77.</citation>
    <PMID>9164184</PMID>
  </reference>
  <reference>
    <citation>Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989 Jan 26;320(4):197-204.</citation>
    <PMID>2643045</PMID>
  </reference>
  <reference>
    <citation>Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol. 1990 Oct;29(2):79-91.</citation>
    <PMID>2249952</PMID>
  </reference>
  <reference>
    <citation>Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, Fujimori Y, Furukawa T, Mineishi S, Matsuo K, Hamajima N, Imamura M. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood. 2003 Aug 15;102(4):1541-7. Epub 2003 Apr 24.</citation>
    <PMID>12714500</PMID>
  </reference>
  <reference>
    <citation>Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987 Jun;43(6):842-7.</citation>
    <PMID>3296349</PMID>
  </reference>
  <reference>
    <citation>Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986 Sep;68(3):770-3.</citation>
    <PMID>3527302</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998 Oct 22;339(17):1186-93.</citation>
    <PMID>9780338</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20;23(15):3447-54. Epub 2005 Mar 7.</citation>
    <PMID>15753458</PMID>
  </reference>
  <reference>
    <citation>Zuckerman T, Rowe JM. Alternative donor transplantation in acute myeloid leukemia: which source and when? Curr Opin Hematol. 2007 Mar;14(2):152-61. Review.</citation>
    <PMID>17255793</PMID>
  </reference>
  <reference>
    <citation>Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008 Jan 1;180(1):163-70.</citation>
    <PMID>18097016</PMID>
  </reference>
  <reference>
    <citation>Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006 Jul 15;66(14):7317-25.</citation>
    <PMID>16849582</PMID>
  </reference>
  <reference>
    <citation>Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res. 2008 Jun 1;14(11):3520-8. doi: 10.1158/1078-0432.CCR-07-4744.</citation>
    <PMID>18519785</PMID>
  </reference>
  <reference>
    <citation>Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120-5. Epub 2004 May 17. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12777.</citation>
    <PMID>15148407</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.</citation>
    <PMID>17242396</PMID>
  </reference>
  <reference>
    <citation>Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, Rhee Fv Fv, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey PJ. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 2004 Feb;33(4):389-96.</citation>
    <PMID>14716338</PMID>
  </reference>
  <reference>
    <citation>Lang P, Greil J, Bader P, Handgretinger R, Klingebiel T, Schumm M, Schlegel PG, Feuchtinger T, Pfeiffer M, Scheel-Walter H, Führer M, Martin D, Niethammer D. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis. 2004 Nov-Dec;33(3):281-7.</citation>
    <PMID>15528145</PMID>
  </reference>
  <reference>
    <citation>Waller EK, Giver CR, Rosenthal H, Somani J, Langston AA, Lonial S, Roback JD, Li JM, Hossain MS, Redei I. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis. 2004 Nov-Dec;33(3):233-7.</citation>
    <PMID>15528137</PMID>
  </reference>
  <reference>
    <citation>Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999 Jun 3;340(22):1704-14.</citation>
    <PMID>10352162</PMID>
  </reference>
  <reference>
    <citation>Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007 Feb 20;25(6):690-7. Epub 2007 Jan 16.</citation>
    <PMID>17228020</PMID>
  </reference>
  <reference>
    <citation>Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Martin PJ, Storb RF, Marr KA. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003 Aug 1;102(3):827-33. Epub 2003 Apr 10.</citation>
    <PMID>12689933</PMID>
  </reference>
  <reference>
    <citation>Dey BR, Spitzer TR. Current status of haploidentical stem cell transplantation. Br J Haematol. 2006 Nov;135(4):423-37. Epub 2006 Sep 19. Review.</citation>
    <PMID>16984391</PMID>
  </reference>
  <reference>
    <citation>Lehnert S, Rybka WB. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transplant. 1994 Apr;13(4):473-7.</citation>
    <PMID>8019473</PMID>
  </reference>
  <reference>
    <citation>Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996 Jul;195(2):129-39. Review.</citation>
    <PMID>8877390</PMID>
  </reference>
  <reference>
    <citation>Mayumi H, Himeno K, Tanaka K, Tokuda N, Fan JL, Nomoto K. Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease. Transplantation. 1987 Aug;44(2):286-90.</citation>
    <PMID>3307052</PMID>
  </reference>
  <reference>
    <citation>Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005.</citation>
    <PMID>18489989</PMID>
  </reference>
  <reference>
    <citation>Lahuerta JJ, Martinez-Lopez J, Serna JD, Bladé J, Grande C, Alegre A, Vazquez L, García-Laraña J, Sureda A, Rubia JD, Conde E, Martinez R, Perez-Equiza K, Moraleda JM, León A, Besalduch J, Cabrera R, Miguel JD, Morales A, García-Ruíz JC, Diaz-Mediavilla J, San-Miguel J. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol. 2000 May;109(2):438-46.</citation>
    <PMID>10848839</PMID>
  </reference>
  <reference>
    <citation>Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.</citation>
    <PMID>12826635</PMID>
  </reference>
  <reference>
    <citation>Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hilde-brandt Y, Atanackovic D, Alchalby H, Ayuk F, Zander AR, Bacher U, Eiermann T. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia. 2011 Oct;25(10):1657-61. doi: 10.1038/leu.2011.138. Epub 2011 Jun 7.</citation>
    <PMID>21647155</PMID>
  </reference>
  <reference>
    <citation>Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008 Feb 1;111(3):1309-17. Epub 2007 Oct 18.</citation>
    <PMID>17947507</PMID>
  </reference>
  <reference>
    <citation>Wu X, Shao Y, Tao Y, Ai G, Wei R, Meng X, Hou J, Han Y, Zhan F, Zheng J, Shi J. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I. Biochem Biophys Res Commun. 2011 Nov 11;415(1):187-92. doi: 10.1016/j.bbrc.2011.10.057. Epub 2011 Oct 18.</citation>
    <PMID>22033416</PMID>
  </reference>
  <reference>
    <citation>Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol. 2009 Mar;155(3):504-13. doi: 10.1111/j.1365-2249.2008.03818.x.</citation>
    <PMID>19220837</PMID>
  </reference>
  <reference>
    <citation>Jardine L, Hambleton S, Bigley V, Pagan S, Wang XN, Collin M. Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk Lymphoma. 2013 Jan;54(1):167-73. doi: 10.3109/10428194.2012.708026. Epub 2012 Sep 8.</citation>
    <PMID>22742576</PMID>
  </reference>
  <reference>
    <citation>Valés-Gómez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 2008 Mar 1;68(5):1546-54. doi: 10.1158/0008-5472.CAN-07-2973.</citation>
    <PMID>18316620</PMID>
  </reference>
  <reference>
    <citation>Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A, San Miguel J. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 2006 May 1;107(9):3575-83. Epub 2005 Nov 10.</citation>
    <PMID>16282346</PMID>
  </reference>
  <reference>
    <citation>Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sanchez C, Rodriguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C, San Miguel JF. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica. 2009 Jul;94(7):975-83. doi: 10.3324/haematol.2008.005017. Epub 2009 Jun 8.</citation>
    <PMID>19508976</PMID>
  </reference>
  <reference>
    <citation>Kim JS, Lee JI, Shin JY, Kim SY, Shin JS, Lim JH, Cho HS, Yoon IH, Kim KH, Kim SJ, Park CG. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation. 2009 Dec 27;88(12):1349-59. doi: 10.1097/TP.0b013e3181bd7b3a.</citation>
    <PMID>20029331</PMID>
  </reference>
  <reference>
    <citation>Blanco B, Sánchez-Abarca LI, Caballero-Velázquez T, Santamaría C, Inogés S, Pérez-Simón JA. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leuk Res. 2011 Oct;35(10):1412-5. doi: 10.1016/j.leukres.2011.05.018. Epub 2011 Jun 11.</citation>
    <PMID>21658766</PMID>
  </reference>
  <reference>
    <citation>Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP 3rd. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10;30(26):3202-8. doi: 10.1200/JCO.2012.42.0984. Epub 2012 Aug 6.</citation>
    <PMID>22869883</PMID>
  </reference>
  <reference>
    <citation>Ohata K, Espinoza JL, Lu X, Kondo Y, Nakao S. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant. 2011 Feb;17(2):205-13. doi: 10.1016/j.bbmt.2010.08.014. Epub 2010 Aug 22.</citation>
    <PMID>20736080</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematologic malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Glycine</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

